Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 8/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ICMT | O60725 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235991 | 0.84 | HTR7 (0.50) | HTR7ALDH1A1 | |
| SCHEMBL24737221 | 0.83 | HTR7 (0.49) | HTR7ALDH1A1 | |
| SCHEMBL11440371 | 0.83 | HTR7 (0.53) | HTR7LMNAHSD17B10ALDH1A1 | |
| SCHEMBL19611198 | 0.82 | HTR7 (0.52) | HTR7TSHRRECQLLMNAALDH1A1 | |
| SCHEMBL21479413 | 0.82 | HTR7 (0.48) | HTR7LMNAALDH1A1 | |
| SCHEMBL13103802 | 0.82 | POLB (0.48) | TSHRRECQLALDH1A1 | |
| SCHEMBL3235980 | 0.79 | HTR7 (0.48) | HTR7L3MBTL1ALDH1A1 | |
| SCHEMBL23373499 | 0.79 | ALDH1A1 (0.46) | HTR7LMNAALDH1A1 | |
| SCHEMBL19611197 | 0.77 | MAPT (0.49) | HTR7L3MBTL1RECQLALDH1A1 | |
| SCHEMBL11138993 | 0.76 | HTR7 (0.51) | HTR7LMNAICMTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954242-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE BROAD INSTITUTE, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200317675-A9 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20190315752-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317675-A9 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK1, SIK2, SIK3 | HTR7 2813/4885TSHR 4652/4885L3MBTL1 3255/4885 |
| US-20190315752-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK1, SIK2, SIK3 | HTR7 2813/4885TSHR 4652/4885L3MBTL1 3255/4885 |
| US-10954242-B2 | Bicyclic urea kinase inhibitors and uses thereof | SIK1, SIK2, SIK3 | HTR7 2813/4885TSHR 4652/4885L3MBTL1 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.